Reboxetine: a norepinephrine selective reuptake pump inhibitor

J Psychiatr Pract. 2004 Jan;10(1):57-63. doi: 10.1097/00131746-200401000-00006.
No abstract available

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Adrenergic Uptake Inhibitors / adverse effects
  • Adrenergic Uptake Inhibitors / pharmacokinetics
  • Adrenergic Uptake Inhibitors / therapeutic use*
  • Animals
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / pharmacokinetics
  • Antidepressive Agents / therapeutic use*
  • Biological Availability
  • Clinical Trials as Topic
  • Cyclopropanes / adverse effects
  • Cyclopropanes / pharmacokinetics
  • Cyclopropanes / therapeutic use
  • Depressive Disorder, Major / blood
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / psychology
  • Drug Approval / legislation & jurisprudence
  • Duloxetine Hydrochloride
  • Humans
  • Metabolic Clearance Rate
  • Milnacipran
  • Morpholines / adverse effects
  • Morpholines / pharmacokinetics
  • Morpholines / therapeutic use*
  • Reboxetine
  • Thiazepines / adverse effects
  • Thiazepines / pharmacokinetics
  • Thiazepines / therapeutic use
  • Thiophenes / adverse effects
  • Thiophenes / pharmacokinetics
  • Thiophenes / therapeutic use
  • United States

Substances

  • Adrenergic Uptake Inhibitors
  • Antidepressive Agents
  • Cyclopropanes
  • Morpholines
  • Thiazepines
  • Thiophenes
  • tianeptine
  • Duloxetine Hydrochloride
  • Reboxetine
  • Milnacipran